Spatial-temporal FUCCI imaging of each cell in a tumor demonstrates locational dependence of cell cycle dynamics and chemoresponsiveness

Cell Cycle

Volumn 13, Issue 13, 2014, Pages 2110-2119

  Yano, Shuya ^a,b,c   Zhang, Yong ^a   Miwa, Shinji ^a,b   Tome, Yasunori ^a,b   Hiroshima, Yukihiko ^a,b   Uehara, Fuminari ^a,b   Yamamoto, Mako ^a,b   Suetsugu, Atsushi ^a,b   Kishimoto, Hiroyuki ^c   Tazawa, Hiroshi ^d   Zhao, Ming ^a   Bouvet, Michael ^b   Fujiwara, Toshiyoshi ^c   Hoffman, Robert M ^a,b  

^a ANTICANCER INC   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c OKAYAMA UNIVERSITY   (Japan)

^d OKAYAMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Cell cycle; Confocal laser microscopy; Dormancy; Drug resistance; Fluorescent proteins; FUCCI; Tumor; Tumor blood vessels

Indexed keywords

CISPLATIN; CYTOTOXIC AGENT; PACLITAXEL; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PHASE; CELL SURFACE; CONTROLLED STUDY; DRUG TARGETING; FLUORESCENCE ANALYSIS; FLUORESCENCE UBIQUITINATION CELL CYCLE INDICATOR; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; REAL TIME ECHOGRAPHY; SCANNING ELECTRON MICROSCOPE; TREATMENT RESPONSE; UBIQUITINATION; VASCULAR TUMOR; ADENOCARCINOMA; ANIMAL; CANCER TRANSPLANTATION; DRUG EFFECTS; FLUORESCENCE IMAGING; LIVER TUMOR; PATHOLOGY; SPATIOTEMPORAL ANALYSIS; TUMOR CELL LINE; XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CISPLATIN; HETEROGRAFTS; HUMANS; LIVER NEOPLASMS; MICE, NUDE; NEOPLASM TRANSPLANTATION; OPTICAL IMAGING; PACLITAXEL; SPATIO-TEMPORAL ANALYSIS;

EID: 84903774507     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.29156     Document Type: Article

References (37)

1. Watson JD. Curing "incurable" cancer. Cancer Discov 2011; 1:477-80; PMID:22586652; http://dx.doi.org/10.1158/2159-8290.CD-11-0220
2. Kyle AH, Baker JHE, Minchinton AI. Targeting quiescent tumor cells via oxygen and IGF-I supplementation. Cancer Res 2012; 72:801-9; PMID:22158947; http://dx.doi.org/10.1158/0008-5472.CAN-11-3059
3. Goss PE, Chambers AF. Does tumour dormancy offer a therapeutic target? Nat Rev Cancer 2010; 10:871-7; PMID:21048784; http://dx.doi.org/10.1038/nrc2933
4. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007; 7:834-46; PMID:17957189; http://dx.doi.org/10. 1038/nrc2256
5. Polzer B, Klein CA. Metastasis awakening: the challenges of targeting minimal residual cancer. Nat Med 2013; 19:274-5; PMID:23467237; http://dx.doi.org/10.1038/nm.3121
6. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer 2012; 12:323-34; PMID:22513401; http://dx.doi.org/10.1038/nrc3261
7. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002; 53:615-27; PMID:11818492; http://dx.doi.org/10.1146/annurev.med.53.082901.103929
8. Naumov GN, Townson JL, MacDonald IC, Wilson SM, Bramwell VH, Groom AC, Chambers AF. Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or latedeveloping metastases. Breast Cancer Res Treat 2003; 82:199-206; PMID:14703067; http://dx.doi.org/10.1023/B:BREA.0000004377. 12288.3c
9. Sakaue-Sawano A, Kurokawa H, Morimura T, Hanyu A, Hama H, Osawa H, Kashiwagi S, Fukami K, Miyata T, Miyoshi H, et al. Visualizing spatiotemporal dynamics of multicellular cell cycle progression. Cell 2008; 132:487-98; PMID:18267078; http://dx.doi.org/10.1016/j.cell.2007.12.033
10. Yano S, Miwa S, Mii S, Hiroshima Y, Uehara F, Yamamoto M, Kishimoto H, Tazawa H, Bouvet M, Fujiwara T, Hoffman RM. Invading cancer cells are predominantly in G0/G1 resulting in chemoresistance demonstrated by real-time FUCCI imaging. Cell Cycle 2014; 13:953-60; PMID:24552821; http://dx.doi.org/10. 4161/cc.27818
11. Yamauchi K, Yang M, Jiang P, Xu M, Yamamoto N, Tsuchiya H, Tomita K, Moossa AR, Bouvet M, Hoffman RM. Development of real-time subcellular dynamic multicolor imaging of cancer-cell trafficking in live mice with a variable-magnification whole-mouse imaging system. Cancer Res 2006; 66:4208-14; PMID:16618743; http://dx.doi.org/10.1158/0008-5472.CAN-05-3927
12. Hoffman RM. The multiple uses of fluorescent proteins to visualize cancer in vivo. Nat Rev Cancer 2005; 5:796-806; PMID:16195751; http://dx.doi.org/10. 1038/nrc1717
13. Condeelis J, Segall JE. Intravital imaging of cell movement in tumours. Nat Rev Cancer 2003; 3:921-30; PMID:14737122; http://dx.doi.org/10.1038/nrc1231
14. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307:58-62; PMID:15637262; http://dx.doi.org/10.1126/science.1104819
15. Yang M, Baranov E, Wang JW, Jiang P, Wang X, Sun FX, Bouvet M, Moossa AR, Penman S, Hoffman RM. Direct external imaging of nascent cancer, tumor progression, angiogenesis, and metastasis on internal organs in the fluorescent orthotopic model. Proc Natl Acad Sci U S A 2002; 99:3824-9; PMID:11891294; http://dx.doi.org/10.1073/pnas.052029099
16. Li L, Mignone J, Yang M, Matic M, Penman S, Enikolopov G, Hoffman RM. Nestin expression in hair follicle sheath progenitor cells. Proc Natl Acad Sci U S A 2003; 100:9958-61; PMID:12904579; http://dx.doi.org/10.1073/pnas.1733025100
17. Amoh Y, Yang M, Li L, Reynoso J, Bouvet M, Moossa AR, Katsuoka K, Hoffman RM. Nestin-linked green fluorescent protein transgenic nude mouse for imaging human tumor angiogenesis. Cancer Res 2005; 65:5352-7; PMID:15958583; http://dx.doi.org/10.1158/0008-5472.CAN-05-0821
18. Mignone JL, Kukekov V, Chiang AS, Steindler D, Enikolopov G. Neural stem and progenitor cells in nestin-GFP transgenic mice. J Comp Neurol 2004; 469:311-24; PMID:14730584; http://dx.doi.org/10.1002/cne.10964
19. Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013; 501:346-54; PMID:24048067; http://dx.doi.org/10.1038/nature12626
20. Bock C, Lengauer T. Managing drug resistance in cancer: lessons from HIV therapy. Nat Rev Cancer 2012; 12:494-501; PMID:22673150; http://dx.doi.org/10. 1038/nrc3297
21. Meads MB, Gatenby RA, Dalton WS. Environmentmediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer 2009; 9:665-74; PMID:19693095; http://dx.doi.org/10.1038/nrc2714
22. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006; 6:583-92; PMID:16862189; http://dx.doi.org/10.1038/nrc1893
23. Kreso A, O'Brien CA, van Galen P, Gan OI, Notta F, Brown AM, Ng K, Ma J, Wienholds E, Dunant C, et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 2013; 339:543-8; PMID:23239622; http://dx.doi.org/10.1126/science.1227670
24. Giedt RJ, Koch PD, Weissleder R. Single cell analysis of drug distribution by intravital imaging. PLoS One 2013; 8:e60988; PMID:23593370; http://dx.doi.org/10.1371/journal.pone.0060988
25. Yokozaki H. Molecular characteristics of eight gastric cancer cell lines established in Japan. Pathol Int 2000; 50:767-77; PMID:11107048; http://dx.doi.org/10.1046/j.1440-1827.2000.01117.x
26. Blagosklonny MV. How cancer could be cured by 2015. Cell Cycle 2005; 4:269-78; PMID:15655345; http://dx.doi.org/10.4161/cc.4.2.1493
27. Blagosklonny MV. Tissue-selective therapy of cancer. Br J Cancer 2003; 89:1147-51; PMID:14520435; http://dx.doi.org/10.1038/sj.bjc.6601256
28. Blagosklonny MV. Matching targets for selective cancer therapy. Drug Discov Today 2003; 8:1104-7; PMID:14678733; http://dx.doi.org/10.1016/S1359- 6446(03)02806-X
29. Blagosklonny MV. "Targeting the absence" and therapeutic engineering for cancer therapy. Cell Cycle 2008; 7:1307-12; PMID:18487952; http://dx.doi.org/10.4161/cc.7.10.6250
30. Blagosklonny MV. Teratogens as anti-cancer drugs. Cell Cycle 2005; 4:1518-21; PMID:16258270; http://dx.doi.org/10.4161/cc.4.11.2208
31. Blagosklonny MV. Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells. Leukemia 2001; 15:936-41; PMID:11417480; http://dx.doi.org/10.1038/sj.leu.2402127
32. Blagosklonny MV. Target for cancer therapy: proliferating cells or stem cells. Leukemia 2006; 20:385-91; PMID:16357832; http://dx.doi.org/10.1038/sj. leu.2404075
33. Blagosklonny MV. Cancer stem cell and cancer stemloids: from biology to therapy. Cancer Biol Ther 2007; 6:1684-90; PMID:18344680; http://dx.doi.org/10. 4161/cbt.6.11.5167
34. Apontes P, Leontieva OV, Demidenko ZN, Li F, Blagosklonny MV. Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. Oncotarget 2011; 2:222-33; PMID:21447859
35. Rao B, van Leeuwen IM, Higgins M, Campbel J, Thompson AM, Lane DP, Lain S. Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy. Oncotarget 2010; 1:639-50; PMID:21317459
36. Blagosklonny MV. NCI's provocative questions on cancer: some answers to ignite discussion. Oncotarget 2011; 2:1352-67; PMID:22267462
37. Blagosklonny MV. Antagonistic drug combinations that select against drug resistance: from bacteria to cancer. Cancer Biol Ther 2007; 6:1013-4; PMID:17646740; http://dx.doi.org/10.4161/cbt.6.7.4340